Literature DB >> 17254521

The operative risk factors in the metabolic syndrome: is it lipids and high BP or are there direct vascular effects of insulin resistance and obesity.

Fabrice M A C Martens1, Frank L J Visseren.   

Abstract

Increase in patients with central obesity and insulin resistance is an important cause for the worldwide increased incidence of type 2 diabetes. Several risk factors such as glucose intolerance, hyperinsulinemia, obesity, dyslipidemia, and hypertension, but also endothelial dysfunction and inflammation, have been found to cluster and often precede type 2 diabetes mellitus. Seeing the importance of early identification, the US National Cholesterol Education Program created a readily applicable definition of the metabolic syndrome for daily clinical practice. It is assumed that the cardiovascular risk for patients belonging to the metabolic syndrome can just be calculated out of the sum of the separate cardiovascular risk factors dyslipidemia and hypertension. However, there are also data pointing toward a higher risk than expected from these separate cardiovascular risk factors because of possible direct vascular effects of insulin resistance and obesity. Awareness of the underlying disorders of insulin resistance and its associated (non-) traditional risk factors such as endothelial dysfunction and inflammation is important for understanding the pathophysiology and thus coherent treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17254521     DOI: 10.1007/s11892-007-0013-7

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  65 in total

Review 1.  American College of Endocrinology position statement on the insulin resistance syndrome.

Authors:  Daniel Einhorn; Gerald M Reaven; Rhoda H Cobin; Earl Ford; Om P Ganda; Yehuda Handelsman; Richard Hellman; Paul S Jellinger; David Kendall; Ronald M Krauss; Naomi D Neufeld; Steven M Petak; Helena W Rodbard; John A Seibel; Donald A Smith; Peter W F Wilson
Journal:  Endocr Pract       Date:  2003 May-Jun       Impact factor: 3.443

2.  Vascular hypertrophy and remodeling in secondary hypertension.

Authors:  D Rizzoni; E Porteri; M Castellano; G Bettoni; M L Muiesan; P Muiesan; S M Giulini; E Agabiti-Rosei
Journal:  Hypertension       Date:  1996-11       Impact factor: 10.190

3.  Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Leonelo Bautista; Maria Grazia Franzosi; Patrick Commerford; Chim C Lang; Zvonko Rumboldt; Churchill L Onen; Liu Lisheng; Supachai Tanomsup; Paul Wangai; Fahad Razak; Arya M Sharma; Sonia S Anand
Journal:  Lancet       Date:  2005-11-05       Impact factor: 79.321

4.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

5.  Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.

Authors:  A Chait; R L Brazg; D L Tribble; R M Krauss
Journal:  Am J Med       Date:  1993-04       Impact factor: 4.965

Review 6.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

7.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

8.  Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates.

Authors:  R Feinstein; H Kanety; M Z Papa; B Lunenfeld; A Karasik
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

9.  The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

Authors:  Cynthia J Girman; Thomas Rhodes; Michele Mercuri; Kalevi Pyörälä; John Kjekshus; Terje R Pedersen; Polly A Beere; Antonio M Gotto; Michael Clearfield
Journal:  Am J Cardiol       Date:  2004-01-15       Impact factor: 2.778

10.  Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin.

Authors:  K Rebrin; G M Steil; L Getty; R N Bergman
Journal:  Diabetes       Date:  1995-09       Impact factor: 9.461

View more
  1 in total

1.  Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. the SMART study.

Authors:  Sandra N Verhagen; Annemarie M J Wassink; Yolanda van der Graaf; Petra M Gorter; Frank L J Visseren
Journal:  Cardiovasc Diabetol       Date:  2011-11-21       Impact factor: 9.951

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.